464 related articles for article (PubMed ID: 28851693)
1. The Antitumor Effects of Vaccine-Activated CD8
Wu S; Zhu W; Peng Y; Wang L; Hong Y; Huang L; Dong D; Xie J; Merchen T; Kruse E; Guo ZS; Bartlett D; Fu N; He Y
Cancer Immunol Res; 2017 Oct; 5(10):908-919. PubMed ID: 28851693
[TBL] [Abstract][Full Text] [Related]
2. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
3. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
4. Differential kinetics of antigen dependency of CD4+ and CD8+ T cells.
Rabenstein H; Behrendt AC; Ellwart JW; Naumann R; Horsch M; Beckers J; Obst R
J Immunol; 2014 Apr; 192(8):3507-17. PubMed ID: 24639353
[TBL] [Abstract][Full Text] [Related]
5. Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo.
Maile R; Siler CA; Kerry SE; Midkiff KE; Collins EJ; Frelinger JA
J Immunol; 2005 Jan; 174(2):619-27. PubMed ID: 15634879
[TBL] [Abstract][Full Text] [Related]
6. Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs.
Miyao K; Terakura S; Okuno S; Julamanee J; Watanabe K; Hamana H; Kishi H; Sakemura R; Koyama D; Goto T; Nishida T; Murata M; Kiyoi H
Cancer Immunol Res; 2018 Jun; 6(6):733-744. PubMed ID: 29653982
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.
Kawano K; Efferson CL; Peoples GE; Carter D; Tsuda N; Murray JL; Ioannides CG
Cancer Res; 2005 Apr; 65(7):2930-7. PubMed ID: 15805296
[TBL] [Abstract][Full Text] [Related]
8. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity.
Salem ML; Kadima AN; Cole DJ; Gillanders WE
J Immunother; 2005; 28(3):220-8. PubMed ID: 15838378
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
10. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
11. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8
Frey AB
Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354
[TBL] [Abstract][Full Text] [Related]
12. High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
Carretero-Iglesia L; Couturaud B; Baumgaertner P; Schmidt J; Maby-El Hajjami H; Speiser DE; Hebeisen M; Rufer N
Front Immunol; 2019; 10():3016. PubMed ID: 31969886
[TBL] [Abstract][Full Text] [Related]
13. Differential in vivo persistence of two subsets of memory phenotype CD8 T cells defined by CD44 and CD122 expression levels.
Walzer T; Arpin C; Beloeil L; Marvel J
J Immunol; 2002 Mar; 168(6):2704-11. PubMed ID: 11884436
[TBL] [Abstract][Full Text] [Related]
14. TCR signal transduction in antigen-specific memory CD8 T cells.
Kersh EN; Kaech SM; Onami TM; Moran M; Wherry EJ; Miceli MC; Ahmed R
J Immunol; 2003 Jun; 170(11):5455-63. PubMed ID: 12759421
[TBL] [Abstract][Full Text] [Related]
15. Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells.
Grayson JM; Zajac AJ; Altman JD; Ahmed R
J Immunol; 2000 Apr; 164(8):3950-4. PubMed ID: 10754284
[TBL] [Abstract][Full Text] [Related]
16. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion.
Shakiba M; Zumbo P; Espinosa-Carrasco G; Menocal L; Dündar F; Carson SE; Bruno EM; Sanchez-Rivera FJ; Lowe SW; Camara S; Koche RP; Reuter VP; Socci ND; Whitlock B; Tamzalit F; Huse M; Hellmann MD; Wells DK; Defranoux NA; Betel D; Philip M; Schietinger A
J Exp Med; 2022 Feb; 219(2):. PubMed ID: 34935874
[TBL] [Abstract][Full Text] [Related]
17. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
18. Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size.
Liu SD; Tomassian T; Bruhn KW; Miller JF; Poirier F; Miceli MC
J Immunol; 2009 May; 182(9):5283-95. PubMed ID: 19380775
[TBL] [Abstract][Full Text] [Related]
19. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
20. Protection against HPV-16-Associated Tumors Requires the Activation of CD8+ Effector Memory T Cells and the Control of Myeloid-Derived Suppressor Cells.
Diniz MO; Sales NS; Silva JR; Ferreira LC
Mol Cancer Ther; 2016 Aug; 15(8):1920-30. PubMed ID: 27222537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
